BioCentury
ARTICLE | Company News

PTAB invalidates Zytiga patent

January 19, 2018 7:34 PM UTC

In an inter partes review (IPR) proceeding, the U.S. Patent Trial and Appeal Board invalidated all 20 claims of U.S. Patent No. 8,822,438 covering prostate cancer drug Zytiga abiraterone acetate from Johnson & Johnson (NYSE:JNJ). PTAB instituted a review of the patent last year, following IPR challenges from Mylan N.V. (NASDAQ:MYL; Tel Aviv:MYL) and other generics makers.

PTAB struck down the patent based on prior art, saying the method described in the patent of administering Zytiga plus prednisone to treat prostate cancer would have been obvious to a person of ordinary skill...